Hemophilia A and hemophilia B are caused by congenital deficiency of factor VIII and factor
IX, respectively, and may lead to recurrent, spontaneous bleeding into the muscles and …

The pharmacokinetic (PK) response to factor VIII (FVIII) and factor IX varies between patients
and this has important clinical implications for treatment. Although PK is affected by patient …

Prevention and treatment of bleeding in hemophilia requires that plasma clotting factor
activity of the replaced factor exceeds a defined target level. Most clinical decisions in …

The aim of this study was to investigate individual pharmacokinetics as a tool for dosing of
factor VIII (FVIII) in severe hemophilia A. It is assumed that effective prophylaxis against …

Dosing decisions for replacement coagulation factors in patients with haemophilia should be
made on an individual patient basis, with the required dose dependent on factors including …

Background: The role of prophylactic factor VIII (FVIII) to decrease hemophilic bleeding and
arthropathy is well established. The rationale for this strategy is to convert patients with …

Clotting factor preparations are expensive and not readily available in all parts of the world.
We are still facing shortages due to limited production. Thus, it is obvious that clotting factor …

Severe haemophilia (factor [F] VIII/FIX activity< 0.01 IU mL− 1) is characterized by repeated
haemarthroses resulting in severe arthropathy in adulthood. In 1958, Professor Nilsson in …

The ISTH SSC on Factor VIII/IX has previously issued guidelines for studies assessing the
pharmacokinetics (PK) of factor concentrates 1., 2.. It suggested drawing 10 or 11 blood …

The primary aim of this study was to investigate the possible relationship between
coagulation factor level and bleeding frequency during prophylactic treatment of …